United States Generic Drugs Market, Forecast 2023-2028, Industry Trends, Growth, Insight, Impact of Inflation, Company Analysis
United States Generic Drugs Market Outlook
United States Generic Drugs Market is projected to reach around US$ 147.57 Billion by 2028, and is expected to grow at a CAGR of 6.39% from 2022 to 2028. The pharmaceutical industry is vital for global healthcare, but it is important to distinguish between factors driving cost increases and those generating savings. Specialty drugs, including biologics, are expensive drugs used for treating complex diseases. However, generic drugs in the US have offered relief from rising drug costs for decades, as competition drives down prices. Generics are cheaper off-patented drugs that are bioequivalent to branded medications.
In the US, they have risen in production due to cost-effectiveness and increased patient access, generating savings for taxpayers, employers, and insurance providers. The number of generic drug approvals has risen, supported by the FDA's Drug Competition Action Plan and the reauthorization of the Generic Drug User Fee Amendments in 2017 to enhance the generic drug development and approval process. In 2022, 91% of US prescriptions were generic drugs, with over 32,000 FDA-approved generic drugs available, partially offsetting large brand drug price increases.
Increasing Prevalence of Life-threatening Diseases in the United States is creating Future Opportunities for the Generic Drug Market
The generic drug market in the United States is witnessing substantial expansion, driven by the growing incidence of chronic illnesses like cardiovascular disease, diabetes, Alzheimer's disease, and Parkinson's disease in the region. The FDA's Generic Drug Program carries out thorough assessments before approval to guarantee that generic medications comply with these guidelines. Moreover, the FDA inspects manufacturing facilities to verify their adherence to agency regulations on good manufacturing practices.
Demand for Branded Generics has been rising in USA, due to the Increasing need for Affordable, High-quality Generic Drugs and the Soaring Healthcare Costs
By Type, United States Generic Drugs Market is segmented into Branded Generics and Unbranded Generics. The growth of the branded generics pharmaceutical industry in the USA is being driven by factors such as moderately high penetration of these drugs and an increasing disease burden among the geriatric population.
Branded generics drugs provide a cost-efficient substitute to costly branded drugs, which is particularly significant in United States with expensive healthcare. Furthermore, the expiration of patents on numerous popular drugs has opened doors for generic drug makers to join the market and provide more affordable options. The industry is also backed by government policies that encourage the use of generics to decrease healthcare expenses.
Inclination towards Generic Drugs to treat heart disease is expected to continue in the United States Pharmaceutical Market
United States Generic Drugs Industry is classified into various therapeutic areas, including Heart Disease, Mental Health, Diabetes, Epilepsy, Cancers, Allergies & Asthma, Chronic Obstructive Pulmonary disease, Alzheimer's disease, HIV/AIDS, and Crohn's Colitis. The demand for generic drugs to treat heart disease is growing due to factors such as the higher occurrence of heart disease, patent expiration of brand-name drugs, and the need for accessible healthcare.
The use of generic drugs for heart disease treatment is being promoted by government policies like the Affordable Care Act. Despite being more affordable, generic drugs are equally safe and effective as brand-name drugs and healthcare providers and patients are turning to them, with statins, beta-blockers, and ACE inhibitors being some of the most frequently prescribed.
Oral and Injectable Generic Drugs markets will continue to grow Simultaneously in the Upcoming Years
By Drug Delivery, USA Generic Drugs Market is divided into Oral, Injectable, Dermal/Topical and Inhalers. Oral and Injectable market share will grow simultaneously in upcoming years, as the demand for affordable and accessible healthcare continues to increase. Factors such as patent expirations of brand-name drugs, increasing healthcare costs, and rising demand for biosimilars may contribute to the growth of both oral and injectable generic drug markets.
Oral generics are widely used and expected to grow due to increasing launches and partnerships like OakrumPharma and ANI Pharmaceuticals' collaboration to create a generic version of Cystadane1, approved by the USFDA in February 2022, which is expected to boost sales and production of oral generics.
Growing emphasis on Self-care and over-the-counter Medications has also contributed to the growth of the U.S. Retail Pharmacy Generic Drugs Market
The US Generic Drugs Industry is fragmented into Specialty Pharmacy, Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy. Retail pharmacy has traditionally dominated the distribution channel segment, with patients preferring to purchase medications from physical stores. The retail pharmacy market has been steadily growing due to patent expirations of branded drugs, increasing healthcare costs, and rising demand for affordable medications. The availability of cheaper generic medicines has led to widespread adoption, especially for chronic diseases like diabetes, cardiovascular diseases, and cancer, which have driven demand for generic drugs.
The shift towards online pharmacy channels and the increasing use of e-prescriptions are also expected to drive the growth of the retail pharmacy generic drugs market in the coming years. There has been a surge in online shopping, including the online distribution of pharmaceutical products.
Growth of the Generic Drugs Market for Adults is the increasing adoption of Biosimilars
By Age Group, USA Generic Drugs Market subdivided into Children (0-19 years), Young Adults (20-39 years), Adults (40-64 years) and seniors (65+ years). The generic drugs market for adults in the United States has been growing steadily over the past few years. In 2022, generic drugs accounted for over 91% of all prescriptions dispensed in the United States.
This indicates a strong demand for affordable medications, which is a key driver of the growth of the generic drugs market. One of the major factors contributing to the growth of the generic drugs market for adults in the US is the increasing number of patent expiries of branded drugs used to treat adult diseases such as cardiovascular disease, diabetes, and cancer.
United States Generic Drug Market Size was valued at US$ 101.77 Billion in 2022
By States, United States Generic Drugs Industry was categorized into California, Texas, New York, Florida, Pennylavania, Ohio, Illionios, North Carolina, Georgia, Michigan and Others. There are several contributing factors to the growth of the generic drugs market in California. One of these factors is the state's efforts to promote generics as a way to save costs. To this end, California has introduced policies such as laws that mandate doctors to prescribe generics when available and programs that encourage pharmacies to promote generic drugs to patients.
Additionally, the market has benefited from the increasing number of patent expiries for branded drugs. This has allowed generic drug manufacturers to enter the market and provide cheaper alternatives, which are in high demand from healthcare providers and patients alike.
Increasing Number of Generic Drugs available in the market has also contributed to the growth of Commercial Payments for Generic drugs
By Payment Type, United States Generic Drugs Market is segmented into Cash, Commercial, Medicare D and Medicaid. The US has seen an increase in commercial payments for generic drugs due to the rising demand for affordable healthcare and prescription drugs. Generic medicines, being less expensive than their brand-name counterparts, are increasingly popular among cost-conscious consumers. This trend is expected to continue due to the increasing availability of generic drugs and incentives provided by insurance companies and healthcare providers.
Key Players Analysis
To stay competitive in the growing market, industry participants are utilizing various tactics including increased investment in research and development, mergers and acquisitions, and product innovations. Major players in the market include Teva Pharmaceuticals, Aurobindo Pharma, Sun Pharmaceuticals, Abbott Laboratories Inc., Lupin Pharmaceuticals Inc., Viatris, Sandoz, and Dr. Reddy's.
Renub Research report title “United States Generic Drugs Market & Forecast By Type (Branded Generics, Unbranded Generics), Therapeutic Area (Heart Disease, Mental Health, Diabetes, Epilepsy, Cancers, Allergies & Asthma, Chronic Obstructive Pulmonary Disease, Alzheimer's Disease, HIV/AIDS, Crohn's colitis), Drug Delivery (Oral, Injectable, Dermal/Topical, Inhalers), Distribution Channel (Specialty Pharmacy, Retail Pharmacy, Hospital Pharmacy, Online Pharmacy) Age Group (Children(0-19 years), Young Adults(20-39 years), Adults (40-64 years), Seniors (65+ years)) States (California, Texas, New York, Florida, Pennylavania, Ohio, Illionios, North Carolina, Georgia, Michigan, Others) Payment Type (Cash, Commercial, Medicare D, Medicaid), Frequency in consumption of generic drugs in United States(Atleast one prescription generic drug consumption monthly-male, female, Three or more prescription generic drug consumption monthly-male, female, Five or more prescription generic drug consumption monthly-male, female), Company (Teva Pharmaceuticals, AurobindoPharma, Sun Pharmaceuticals, Abbott Laboratories Inc., Lupin Pharmaceuticals Inc., Viatris, Sandoz, and Dr. Reddy's)” provides an all-encompassing analysis on the United States Generic Drug Industry.
Type: Market breakup in 2 viewpoints
1. Branded Generics
2. Unbranded Generics
Therapeutic Area: Market breakup from 10 viewpoints
1. Heart Disease
2. Mental Health
3. Diabetes
4. Epilepsy
5. Cancers
6. Allergies & Asthma
7. Chronic Obstructive Pulmonary Disease
8. Alzheimer Disease
9. HIV/AIDS
10. Crohn's colitis
Drug Delivery: Market breakup from 4 viewpoints
1. Oral
2. Injectable
3. Dermal/Topical
4. Inhalers
Distribution Channel: Market breakup from 4 viewpoints
1. Specialty Pharmacy
2. Retail Pharmacy
3. Hospital Pharmacy
4. Online Pharmacy
Age Group: Market breakup from 4 viewpoints
1. Children (0-19 years)
2. Young Adults (20-39 years)
3. Adults (40-64 years)
4. Seniors (65+ years)
States: Market breakup from 11 States
1. California
2. Texas
3. New York
4. Florida
5. Pennylavania
6. Ohio
7. Illionios
8. North Carolina
9. Georgia
10. Michigan
11. Others
Payment Type: Market breakup from 4 viewpoints
1. Cash
2. Commercial
3. Medicare D
4. Medicaid
Frequency in consumption of Generic Drugs in United States
1. At least 1 prescription generic drugs consumption monthly
a. Male
b. Female
2. Three or more prescription generic drugs consumption monthly
a. Male
b. Female
3. Five or more Prescription generic drugs consumption monthly
a. Male
b. Female
All the Company Analysis have covered 3 Viewpoints
• Overview
• Recent Developments
• Revenue Analysis
Company Analysis
1. Teva Pharmaceuticals
2. AurobindoPharma
3. Sun Pharmaceuticals
4. Abbott Laboratories Inc
5. Lupin Pharmaceuticals Inc
6. Viatris
7. Sandoz
8. Dr. Reddy's.
Report Details:
| Report Features | Details |
| Base Year | 2022 |
| Historical Period | 2018 - 2022 |
| Forecast Period | 2023 - 2028 |
| Market | US$ Billion |
| Segment Covered | Type, Therapeutic Area, Drug Delivery, Distribution Channel, Age Group, States, and Payment Type |
| States Covered | California, Texas, New York, Florida, Pennylavania, Ohio, Illionios, North Carolina, Georgia, Michigan, Others |
| Companies Covered | Teva Pharmaceuticals, Aurobindo Pharma, Sun Pharmaceuticals, Abbott Laboratories Inc., Lupin Pharmaceuticals Inc., Viatris, Sandoz, and Dr. Reddy's |
| Customization Scope | 20% Free Customization |
| Post-Sale Analyst Support | 1 Year (52 Weeks) |
| Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on request) |
1. Introduction
2. Why is the US Generic Drug Market So Lucrative
3. Research & Methodology
4. Executive Summary
5. Market Dynamics
5.1 Growth Drivers
5.2 Challenges
6. Porter’s Five Forces Analysis- United States Generic Drugs Market
6.1 Bargaining Power of Buyers
6.2 Bargaining Power of Suppliers
6.3 Degree of Rivalry
6.4 Threat of New Entrants
6.5 Threat of Substitutes
7. SWOT Analysis- United States Generic Drugs Market
7.1 Strengths
7.2 Weaknesses
7.3 Opportunities
7.4 Threats
8. United States Generic Drugs Market
9. Market Share – United States Generic Drugs Analysis
9.1 By Type
9.2 By Therapeutic Area
9.3 By Drug Delivery
9.4 By Distribution Channel
9.5 By Age Group
9.6 By State
9.7 By Payment Type
10. Type- United States Generic Drugs Market
10.1 Branded Generics
10.2 Unbranded Generics
11. Therapeutic Area- United States Generic Drugs Market
11.1 Heart Disease
11.2 Mental Health
11.3 Diabetes
11.4 Epilepsy
11.5 Cancers
11.6 Allergies &Asthama
11.7 Chronic Obstructive Pulmonary Diesase
11.8 Alzheimer's Disease
11.9 HIV/AIDS
11.10 Crohn's colitis
12. Drug Delivery- United States Generic Drugs Market
12.1 Oral
12.2 Injectables
12.3 Dermal/Topical
12.4 Inhalers
13. Distribution Channel- United States Generic Drugs Market
13.1 Specialty Pharmacy
13.2 Retail Pharmacy
13.3 Hospital Pharmacy
13.4 Online Pharmacy
14. Age Group- United States Generic Drugs Market
14.1 Children (0-19 years)
14.2 Young Adults (20-39 years)
14.3 Adults (40-64 years)
14.4 Seniors (Above 65 years)
15. State- United States Generic Drugs Market
15.1 California
15.2 Texas
15.3 New York
15.4 Florida
15.5 Pennylavania
15.6 Ohio
15.7 Illionios
15.8 North Carolina
15.9 Georgia
15.10 Michigan
15.11 Others
16. Payment Type- United States Generic Drugs Market
16.1 Cash
16.2 Commercial
16.3 Medicaid
16.4 Medicare D
17. Frequency in consumption of Generic Drugs in United States
17.1 At least 1 prescription generic drugs consumption monthly
17.1.1 Male
17.1.2 Female
17.2 Three or more prescription generic drugs consumption monthly
17.2.1 Male
17.2.2 Female
17.3 Five or more Prescription generic drugs consumption monthly
17.3.1 Male
17.3.2 Female
18. US Generic Drug Market- Competitive Landscape
18.1 US Generic Drug Market - Competitive Structure
18.2 US Generic Drug Market - Breakup of Key Players
18.3 US Generic Drug Market - Most Prescribed Generic Drugs
18.4 US Generic Drug Market - Market Breakup by Distribution
18.5 US Generic Drug Market - Pricing Dynamics
19. Regulations in the US Generic Drug Industry
19.1 Overview of Pharmaceutical Regulations
19.2 Drug Applications
19.3 Patents and Market Exclusivity
19.4 Regulatory Requirements for Generic Drugs
19.5 The Hatch-Waxman Act
19.6 Certifications
19.7 Other Important Considerations
20. Key Players Analysis
20.1 Teva Pharmaceuticals
20.1.1 Overview
20.1.2 Recent Development
20.1.3 Sales Analysis
20.2 Aurobindo Pharma
20.2.1 Overview
20.2.2 Recent Development
20.2.3 Sales Analysis
20.3 Sun Pharmaceuticals
20.3.1 Overview
20.3.2 Recent Development
20.3.3 Sales Analysis
20.4 Abbott Laboratories Inc
20.4.1 Overview
20.4.2 Recent Development
20.4.3 Sales Analysis
20.5 Lupin Pharmaceuticals, Inc
20.5.1 Overview
20.5.2 Recent Development
20.5.3 Sales Analysis
20.6 Viatris
20.6.1 Overview
20.6.2 Recent Development
20.6.3 Sales Analysis
20.7 Sandoz
20.7.1 Overview
20.7.2 Recent Development
20.7.3 Sales Analysis
20.8 Dr. Reddy’s
20.8.1 Overview
20.8.2 Recent Development
20.8.3 Sales Analysis
List of Figures:
Figure-01: United States – Generic Drugs Market (Billion US$), 2018 – 2022
Figure-02: United States – Forecast for Generic Drugs Market (Billion US$), 2023 – 2028
Figure-03: Type – Branded Generics Market (Billion US$), 2018 – 2022
Figure-04: Type – Forecast for Branded Generics Market (Billion US$), 2023 – 2028
Figure-05: Type – Unbranded Generics Market (Billion US$), 2018 – 2022
Figure-06: Type – Forecast for Unbranded Generics Market (Billion US$), 2023 – 2028
Figure-07: Therapeutic Area – Heart Disease Market (Billion US$), 2018 – 2022
Figure-08: Therapeutic Area – Forecast for Heart Disease Market (Billion US$), 2023 – 2028
Figure-09: Therapeutic Area – Mental Health Market (Billion US$), 2018 – 2022
Figure-10: Therapeutic Area – Forecast for Mental Health Market (Billion US$), 2023 – 2028
Figure-11: Therapeutic Area – Diabetes Market (Billion US$), 2018 – 2022
Figure-12: Therapeutic Area – Forecast for Diabetes Market (Billion US$), 2023 – 2028
Figure-13: Therapeutic Area – Epilepsy Market (Billion US$), 2018 – 2022
Figure-14: Therapeutic Area – Forecast for Epilepsy Market (Billion US$), 2023 – 2028
Figure-15: Therapeutic Area – Cancers Market (Billion US$), 2018 – 2022
Figure-16: Therapeutic Area – Forecast for Cancers Market (Billion US$), 2023 – 2028
Figure-17: Therapeutic Area – Allergies &Asthama Market (Billion US$), 2018 – 2022
Figure-18: Therapeutic Area – Forecast for Allergies &Asthama Market (Billion US$), 2023 – 2028
Figure-19: Therapeutic Area – Chronic Obstructive Pulmonary Diesase Market (Billion US$), 2018 – 2022
Figure-20: Therapeutic Area – Forecast for Chronic Obstructive Pulmonary Diesase Market (Billion US$), 2023 – 2028
Figure-21: Therapeutic Area – Alzheimer's Disease Market (Billion US$), 2018 – 2022
Figure-22: Therapeutic Area – Forecast for Alzheimer's Disease Market (Billion US$), 2023 – 2028
Figure-23: Therapeutic Area – HIV/AIDS Market (Billion US$), 2018 – 2022
Figure-24: Therapeutic Area – Forecast for HIV/AIDS Market (Billion US$), 2023 – 2028
Figure-25: Therapeutic Area – Crohn's colitis Market (Billion US$), 2018 – 2022
Figure-26: Therapeutic Area – Forecast for Crohn's colitis Market (Billion US$), 2023 – 2028
Figure-27: Drug Delivery – Oral Market (Billion US$), 2018 – 2022
Figure-28: Drug Delivery – Forecast for Oral Market (Billion US$), 2023 – 2028
Figure-29: Drug Delivery – Injectables Market (Billion US$), 2018 – 2022
Figure-30: Drug Delivery – Forecast for Injectables Market (Billion US$), 2023 – 2028
Figure-31: Drug Delivery – Dermal/Topical Market (Billion US$), 2018 – 2022
Figure-32: Drug Delivery – Forecast for Dermal/Topical Market (Billion US$), 2023 – 2028
Figure-33: Drug Delivery – Inhalers Market (Billion US$), 2018 – 2022
Figure-34: Drug Delivery – Forecast for Inhalers Market (Billion US$), 2023 – 2028
Figure-35: Distribution Channel – Specialty Pharmacy Market (Billion US$), 2018 – 2022
Figure-36: Distribution Channel – Forecast for Specialty Pharmacy Market (Billion US$), 2023 – 2028
Figure-37: Distribution Channel – Retail Pharmacy Market (Billion US$), 2018 – 2022
Figure-38: Distribution Channel – Forecast for Retail Pharmacy Market (Billion US$), 2023 – 2028
Figure-39: Distribution Channel – Hospital Pharmacy Market (Billion US$), 2018 – 2022
Figure-40: Distribution Channel – Forecast for Hospital Pharmacy Market (Billion US$), 2023 – 2028
Figure-41: Distribution Channel – Online Pharmacy Market (Billion US$), 2018 – 2022
Figure-42: Distribution Channel – Forecast for Online Pharmacy Market (Billion US$), 2023 – 2028
Figure-43: Age Group – Children (0-19 years) Market (Billion US$), 2018 – 2022
Figure-44: Age Group – Forecast for Children (0-19 years) Market (Billion US$), 2023 – 2028
Figure-45: Age Group – Young Adults (20-39 years) Market (Billion US$), 2018 – 2022
Figure-46: Age Group – Forecast for Young Adults (20-39 years) Market (Billion US$), 2023 – 2028
Figure-47: Age Group – Adults (40-64 years) Market (Billion US$), 2018 – 2022
Figure-48: Age Group – Forecast for Adults (40-64 years) Market (Billion US$), 2023 – 2028
Figure-49: Age Group – Seniors (Above 65 years) Market (Billion US$), 2018 – 2022
Figure-50: Age Group – Forecast for Seniors (Above 65 years) Market (Billion US$), 2023 – 2028
Figure-51: California – Generic Drugs Market (Billion US$), 2018 – 2022
Figure-52: California – Forecast for Generic Drugs Market (Billion US$), 2023 – 2028
Figure-53: Texas – Generic Drugs Market (Billion US$), 2018 – 2022
Figure-54: Texas – Forecast for Generic Drugs Market (Billion US$), 2023 – 2028
Figure-55: New York – Generic Drugs Market (Billion US$), 2018 – 2022
Figure-56: New York – Forecast for Generic Drugs Market (Billion US$), 2023 – 2028
Figure-57: Florida – Generic Drugs Market (Billion US$), 2018 – 2022
Figure-58: Florida – Forecast for Generic Drugs Market (Billion US$), 2023 – 2028
Figure-59: Pennylavania – Generic Drugs Market (Billion US$), 2018 – 2022
Figure-60: Pennylavania – Forecast for Generic Drugs Market (Billion US$), 2023 – 2028
Figure-61: Ohio – Generic Drugs Market (Billion US$), 2018 – 2022
Figure-62: Ohio – Forecast for Generic Drugs Market (Billion US$), 2023 – 2028
Figure-63: Illionios – Generic Drugs Market (Billion US$), 2018 – 2022
Figure-64: Illionios – Forecast for Generic Drugs Market (Billion US$), 2023 – 2028
Figure-65: North Carolina – Generic Drugs Market (Billion US$), 2018 – 2022
Figure-66: North Carolina – Forecast for Generic Drugs Market (Billion US$), 2023 – 2028
Figure-67: Georgia – Generic Drugs Market (Billion US$), 2018 – 2022
Figure-68: Georgia – Forecast for Generic Drugs Market (Billion US$), 2023 – 2028
Figure-69: Michigan – Generic Drugs Market (Billion US$), 2018 – 2022
Figure-70: Michigan – Forecast for Generic Drugs Market (Billion US$), 2023 – 2028
Figure-71: Others – Generic Drugs Market (Billion US$), 2018 – 2022
Figure-72: Others – Forecast for Generic Drugs Market (Billion US$), 2023 – 2028
Figure-73: Payment Type – Cash Market (Billion US$), 2018 – 2022
Figure-74: Payment Type – Forecast for Cash Market (Billion US$), 2023 – 2028
Figure-75: Payment Type – Commercial Market (Billion US$), 2018 – 2022
Figure-76: Payment Type – Forecast for Commercial Market (Billion US$), 2023 – 2028
Figure-77: Payment Type – Medicaid Market (Billion US$), 2018 – 2022
Figure-78: Payment Type – Forecast for Medicaid Market (Billion US$), 2023 – 2028
Figure-79: Payment Type – Medicare D Market (Billion US$), 2018 – 2022
Figure-80: Payment Type – Forecast for Medicare D Market (Billion US$), 2023 – 2028
Figure-81: Male – At least One prescription generic drugs consumption monthly Market (Frequency), 2018 – 2022
Figure-82: Male – Forecast for At least One prescription generic drugs consumption monthly Market (Frequency), 2023 – 2028
Figure-83: Female – At least One prescription generic drugs consumption monthly Market (Frequency), 2018 – 2022
Figure-84: Female – Forecast for At least One prescription generic drugs consumption monthly Market (Frequency), 2023 – 2028
Figure-85: Male – Three or more prescription generic drugs consumption monthly Market (Frequency), 2018 – 2022
Figure-86: Male – Forecast for Three or more prescription generic drugs consumption monthly Market (Frequency), 2023 – 2028
Figure-87: Female – Three or more prescription generic drugs consumption monthly Market (Frequency), 2018 – 2022
Figure-88: Female – Forecast for Three or more prescription generic drugs consumption monthly Market (Frequency), 2023 – 2028
Figure-89: Male – Five or more Prescription generic drugs consumption monthly Market (Frequency), 2018 – 2022
Figure-90: Male – Forecast for Five or more Prescription generic drugs consumption monthly Market (Frequency), 2023 – 2028
Figure-91: Female – Five or more Prescription generic drugs consumption monthly Market (Frequency), 2018 – 2022
Figure-92: Female – Forecast for Five or more Prescription generic drugs consumption monthly Market (Frequency), 2023 – 2028
Figure-93: Teva Pharmaceuticals – Global Revenue (Billion US$), 2018 – 2022
Figure-94: Teva Pharmaceuticals – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-95: AurobindoPharma – Global Revenue (Billion US$), 2018 – 2022
Figure-96: AurobindoPharma – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-97: Sun Pharmaceuticals – Global Revenue (Billion US$), 2018 – 2022
Figure-98: Sun Pharmaceuticals – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-99: Abbott Laboratories Inc – Global Revenue (Billion US$), 2018 – 2022
Figure-100: Abbott Laboratories Inc – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-101: Lupin Pharmaceuticals, Inc – Global Revenue (Billion US$), 2018 – 2022
Figure-102: Lupin Pharmaceuticals, Inc – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-103: Viatris – Global Revenue (Billion US$), 2018 – 2022
Figure-104: Viatris – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-105: Sandoz – Global Revenue (Billion US$), 2018 – 2022
Figure-106: Sandoz – Forecast for Global Revenue (Billion US$), 2023 – 2028
Figure-107: Dr. Reddy’s – Global Revenue (Billion US$), 2018 – 2022
Figure-108: Dr. Reddy’s – Forecast for Global Revenue (Billion US$), 2023 – 2028
List of Tables:
Table-01: United States – Generic Drugs Market Share by Type (Percent), 2018 – 2022
Table-02: United States – Forecast for Generic Drugs Market Share by Type (Percent), 2023 – 2028
Table-03: United States – Generic Drugs Market Share by Therapeutic Area (Percent), 2018 – 2022
Table-04: United States – Forecast for Generic Drugs Market Share by Therapeutic Area (Percent), 2023 – 2028
Table-05: United States – Generic Drugs Market Share by Drug Delivery (Percent), 2018 – 2022
Table-06: United States – Forecast for Generic Drugs Market Share by Drug Delivery (Percent), 2023 – 2028
Table-07: United States – Generic Drugs Market Share by Distribution Channel (Percent), 2018 – 2022
Table-08: United States – Forecast for Generic Drugs Market Share by Distribution Channel (Percent), 2023 – 2028
Table-09: United States – Generic Drugs Market Share by Age Group (Percent), 2018 – 2022
Table-10: United States – Forecast for Generic Drugs Market Share by Age Group (Percent), 2023 – 2028
Table-11: United States – Generic Drugs Market Share by State (Percent), 2018 – 2022
Table-12: United States – Forecast for Generic Drugs Market Share by State (Percent), 2023 – 2028
Table-13: United States – Generic Drugs Market Share by Payment Type (Percent), 2018 – 2022
Table-14: United States – Forecast for Generic Drugs Market Share by Payment Type (Percent), 2023 – 2028
Reach out to us
Call us on
USA: +1-678-302-0700
INDIA: +91-120-421-9822
Drop us an email at
info@renub.com